Dec 04, 2019 - The rare-disease specialist is putting together a respectable end-of-year run.
Nov 29, 2019 - The biotech space of the broad healthcare sector outperformed others in November, courtesy of a series of positive news including study results, regulatory backdrop and deal activities.
Nov 29, 2019 - The Zacks Analyst Blog Highlights: GLD, CRSP, GBT, ALNY and ARKG
Nov 27, 2019 - Why Gold is Headed to Zero -- And What You Should Buy Instead
Nov 26, 2019 - There’s still a long way to go, but the newcomer is off to a good start.
Nov 25, 2019 - The release of encouraging data on the CRISPR/Cas9 gene-editing therapy CTX001 for two severe blood disorders puts emphasis on some genomic ETFs.
Nov 21, 2019 - The French reimbursement for Vertex's (VRTX) cystic fibrosis medicine Orkambi removes a key overhang for the stock.
Nov 20, 2019 - Vertex (VRTX) and partner CRISPR Therapeutics announce positive early data from two studies on gene-editing drug CTX001 for the treatment of beta-thalassemia and sickle cell disease.
Nov 20, 2019 - Companies in the news are: AMD, SAEX, DSS, CRSP
Nov 20, 2019 - Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.